Article

Acute Myeloid Leukemia With t(6;9)(p23;q34) Is Associated With Dysplasia and a High Frequency of flt3 Gene Mutations

Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
American Journal of Clinical Pathology (Impact Factor: 3.01). 10/2004; 122(3):348-58. DOI: 10.1309/5DGB-59KQ-A527-PD47
Source: PubMed

ABSTRACT We report 12 cases of t(6;9)(p23;q34)-positive acute myeloid leukemia (AML), all classified using the criteria of the World Health Organization classification. There were 10 women and 2 men with a median age of 51 years (range, 20-76 years). Dysplasia was present in all cases (9 previously untreated), and basophilia was present in 6 (50%). Immunophenotypic studies showed that the blasts were positive for CD9, CD13, CD33, CD38, CD117, and HLA-DR in all cases assessed. CD34 was positive in 11 (92%) of 12, and terminal deoxynucleotidyl transferase was positive in 7 (64%) of 11 cases. The t(6;9) was the only cytogenetic abnormality detected in 7 cases (58%), and 5 cases had additional chromosomal abnormalities. Of 8 cases assessed, 7 (88%) had flt3 gene mutations. We conclude that t(6;9)-positive AML cases have distinctive morphologic features, an immunophenotype suggesting origin from an early hematopoietic progenitor cell, and a high frequency of flt3 gene mutations.

Download full-text

Full-text

Available from: L. Jeffrey Medeiros, Aug 26, 2015
1 Follower
 · 
166 Views
  • Source
    • "FLT3-ITD mutations have been reported in 20e30% of younger adult patients with AML, and FLT3/ TKD (D835) mutations in 7% [22]. These mutations have an adverse impact on prognosis and have been reported in 71e88 % of patients with the t(6;9) [1] [9]. FLT3 mutations were present in 54% of our patients, all of whom had FLT3 eITD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Among patients with acute myeloid leukemia (AML), the t(6;9) (p22;q34) is a rare but defined subset with a poor prognosis. We report 16 patients with the t(6;9), of whom 13 had AML, 2 had myelodysplastic syndrome (MDS), and 1 had chronic myeloid leukemia in myeloid blast crisis (CML-BC). All except for one were evaluated at diagnosis. The median age was 34.5 (range: 7-62 years), with 12 adults and 12 males. Trilineage dysplasia was present in 13 (81%). Marrow basophilia was seen in only two patients, one of whom had CML-BC. HLA-DR was positive in all 12 patients assessed, CD33 in 11, CD13 in 10, and CD34 in seven. Four patients had one other abnormality apart from the t(6;9). These were the t(9;22) in the patient with CML and deletion 9q, addition 13q, and an isochromosome 8q in the other three patients. There were no complex karyotypes. Fms-related tyrosine kinase 3--internal tandem duplication (FLT3-ITD) mutations were seen in seven of 13 patients. Follow-up details were available for six patients. Three received palliative care, and follow-up details were not available for the other seven. The response to chemotherapy was poor in the remaining patients. The only patients who survived were three out of the four who had allogeneic hematopoietic stem cell transplantation (HSCT).
    Cancer genetics and cytogenetics 12/2010; 203(2):297-302. DOI:10.1016/j.cancergencyto.2010.08.012 · 1.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With emergence of biomedical informatics, Web intelligence, and E-business, new challenges are coming for knowledge discovery and data mining modeling problems. In this dissertation work, a framework named Granular Support Vector Machines (GSVM) is proposed to systematically and formally combine statistical learning theory, granular computing theory and soft computing theory to address challenging predictive data modeling problems effectively and/or efficiently, with specific focus on binary classification problems. In general, GSVM works in 3 steps. Step 1 is granulation to build a sequence of information granules from the original dataset or from the original feature space. Step 2 is modeling Support Vector Machines (SVM) in some of these information granules when necessary. Finally, step 3 is aggregation to consolidate information in these granules at suitable abstract level. A good granulation method to find suitable granules is crucial for modeling a good GSVM. Under this framework, many different granulation algorithms including the GSVM-CMW (cumulative margin width) algorithm, the GSVM-AR (association rule mining) algorithm, a family of GSVM-RFE (recursive feature elimination) algorithms, the GSVM-DC (data cleaning) algorithm and the GSVM-RU (repetitive undersampling) algorithm are designed for binary classification problems with different characteristics. The empirical studies in biomedical domain and many other application domains demonstrate that the framework is promising. As a preliminary step, this dissertation work will be extended in the future to build a Granular Computing based Predictive Data Modeling framework (GrC-PDM) with which we can create hybrid adaptive intelligent data mining systems for high quality prediction. Text (Thesis). System requirements: PC, World Wide Web browser and PDF reader. Mode of access: World Wide Web. Title from title screen. Yan-Qing Zhang, committee chair; Raj Sunderraman, Robert Harrison, Yichuan Zhao, committee members. Electronic text (175 p. : ill. (some col.)). Thesis (Ph. D.)--Georgia State University, 2005. Includes bibliographical references (p. 163-175). Description based on contents viewed Apr. 30, 2007.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leukemias are monoclonal neoplasms that arise as a result of acquired mutations in hematopoietic progenitor cells. Approximately 25,000 to 30,000 new cases of leukemia are diagnosed in the United States each year (1). Clinically, leukemias can be divided into acute and chronic neoplasms. Patients with acute leukemia usually present with an abrupt onset of symptoms attributable to bone marrow failure. Thus, patients can present with anemia, leukopenia, or thrombocytopenia. The neoplastic cells are immature blasts and the disease is aggressive, requiring immediate and aggressive chemotherapy. By contrast, patients with chronic leukemia have more gradual onset of symptoms, usually without bone marrow failure initially, and the neoplastic cells are differentiated (e.g., maturing granulocytes or small lymphocytes). Therapy for chronic leukemias is typically less aggressive at onset and is not needed for some patients (e.g., chronic lymphocytic leukemia), although eventually patients usually require therapy for either massive tumor burden or transformation to a higher-grade tumor. Traditionally, morphologic, cytochemical, and immunophe-notypic methods have been used to divide acute and chronic leukemias according to myeloid or lymphoid lineage. Of these four broad groups, acute myeloid leukemia (AML) is most common, approx 10,000 new cases diagnosed per year (Fig. 1), followed by chronic lymphocytic leukemia (CLL), with 8000 new cases per year, chronic myelogenous leukemia (CML), with 4500 new cases per year, and acute lymphoblastic leukemia (ALL), with 3100 new cases per year (1).
    12/2004: pages 415-436;
Show more